 Home > Encyclopedia > Refametinib

Refametinib

Refametinib structure

CAS No:
923032-37-5
Formula:
C19H20F3IN2O5S
Chemical Name:
Refametinib
Synonyms:
Cyclopropanesulfonamide,N-[3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]-;N-[3,4-Difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropanesulfonamide;RDEA 119;BAY 8697661;BAY 869766;Refametinib;N-[3,4-Difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide;Bay 86-9766;2378555-40-7
Categories:
Biochemical Engineering > Inhibitors

Description

Refametinib is a potent, selective, allosteric MEK1/MEK2 inhibitor with IC50s of 19 nM and 47 nM, respectively.

Refametinib is an orally bioavailable selective MEK inhibitor with potential antineoplastic activity. Refametinib specifically inhibits mitogen-activated protein kinase kinase 1 (MAP2K1 or MAPK/ERK kinase 1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual specificity threonine/tyrosine kinase, is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.

Refametinib Basic Attributes

Molecular Weight：

572.3371796

Exact Mass：

572.34

UNII：

JPX07AFM0N

DSSTox ID：

DTXSID40238961

NCI Thesaurus Code：

C74059

Characteristics

PSA：

116

XLogP3：

2.8

Density：

1.8±0.1 g/cm3

Flash Point：

296.7±32.9 °C

Refractive Index：

1.660

Safety Information

Precautionary statement(s)：

P201, P202, P260, P264, P270, P281, P308+P313, P314, P405, P501

Hazard Statements：

H361

GHS Classification：

|Danger|H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]|P201, P202, P260, P264, P270, P281, P308+P313, P314, P405, and P501|Aggregated GHS information provided by 25 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Drug Information

Drug Indication：

Investigated for use/treatment in cancer/tumors (unspecified).

Mechanism of Action：

RDEA119 is a potent, non-ATP competitive, highly selective inhibitor of MEK. RDEA119 is a highly potent and selective inhibitor of mitogen-activated ERK kinase (MEK), a key component of the RAS/RAF/MEK/ERK pathway that is commonly defective in human tumors. The MEK1/2 pathway is important in cell cycle regulation in inflammatory bowel disease, including ulcerative colitis and Crohn's disease. RDEA119 was shown to reduce damage to colonic tissue in two different mouse models of colitis, murine trinitrobenzene sulfonic acid (TNBS) colitis model and murine dextran sulfate sodium (DSS) colitis model. [Ardea Biosciences Inc. Press release]

MeSH Entry Terms：

BAY 869766

Computed Properties

Molecular Weight:572.3
XLogP3:2.8
Hydrogen Bond Donor Count:4
Hydrogen Bond Acceptor Count:10
Rotatable Bond Count:9
Exact Mass:572.00897
Monoisotopic Mass:572.00897
Topological Polar Surface Area:116
Heavy Atom Count:31
Complexity:711
Defined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes